Muscarinic receptor blockade attenuates reserpine-mediated Fos induction in the rat striatopallidal pathway.
Acute administration of the dopamine-depleting agent reserpine (10 mg/kg) induces Fos expression in striatopallidal neurons of intact rats-an effect that is blocked by pretreatment with the D2 agonist quinpirole (0.5 mg/kg). Systemic administration of the muscarinic antagonist scopolamine (50 mg/kg) partially attenuates reserpine-mediated striatal Fos expression. These data suggest that muscarinic receptors, either within the striatum or in extrastriatal sites, regulate D2 receptor-mediated Fos expression in rat striatopallidal neurons.
Pollack
Alexia E
AE
Department of Biology, University of Massachusetts-Boston, Boston, MA 02125, USA. alexia.pollack@umb.edu
Angerer
Michael R
MR
D018759:Adrenergic Uptake Inhibitors / Q000494:pharmacology; D000818:Animals; D004298:Dopamine / Q000378:metabolism; D018491:Dopamine Agonists / Q000494:pharmacology; D004347:Drug Interactions / Q000502:physiology; D005917:Globus Pallidus / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D018727:Muscarinic Antagonists / Q000494:pharmacology*; D017072:Neostriatum / Q000187:drug effects* / Q000378:metabolism; D009434:Neural Pathways / Q000187:drug effects / Q000378:metabolism; D016760:Proto-Oncogene Proteins c-fos / Q000187:drug effects* / Q000378:metabolism; D019257:Quinpirole / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017448:Receptors, Dopamine D2 / Q000819:agonists / Q000378:metabolism; D011976:Receptors, Muscarinic / Q000187:drug effects* / Q000378:metabolism; D012110:Reserpine / Q000494:pharmacology*; D012601:Scopolamine / Q000494:pharmacology
D018759:Adrenergic Uptake Inhibitors; D018491:Dopamine Agonists; D018727:Muscarinic Antagonists; D016760:Proto-Oncogene Proteins c-fos; D017448:Receptors, Dopamine D2; D011976:Receptors, Muscarinic; D019257:Quinpirole; D012110:Reserpine; D012601:Scopolamine; D004298:Dopamine